Skip to main content
. 2020 Apr 23;55:102755. doi: 10.1016/j.ebiom.2020.102755

Table 3.

Tumor response based on investigator assessments.

Objective response 100 mg 150 mg 200 mg Total
(n = 3) (n = 3) (n = 13) (n = 19)
CR 0 0 0 0
PR 1 (33%) 0 5 (39%) 6 (32%)
SD 2 (67%) 3 (100%) 8 (62) 13 (68)
PD 0 0 0 0
ORR (95%CI) 33% (1−91%) 0 (0–71%) 39% (14−68%) 32% (13−57%)
DCR (95%CI) 100% (29−100%) 100% (29−100%) 100.0 (75−100%) 100.0 (82−100%)
PFS (month, 95%CI) 4.6 (3.7-NA) 5.5 (2.6–13.0) 5.7 (4.8–16.7) 5.6 (4.6–13)